By ONN Staff

September 29, 2022

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from September 2022.

September 26, 2022

On September 22 and 23, 2022, the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened for a hearing to assess the risk-benefit ratio of 3 agents.

August 31, 2022

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from August 2022.

July 30, 2022

In the modern era, the number of patients with diffuse large B-cell lymphoma who will derive benefit from autologous stem cell transplantation is small, according to Jeremy S. Abramson, MD, MMSc.

July 29, 2022

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from July 2022.

July 23, 2022

Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

July 21, 2022

A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.

July 21, 2022

Patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved superior progression-free survival with zanubrutinib vs a combination of bendamustine plus rituximab.

April 21, 2022

PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.

April 20, 2022

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.